AUS
NZ
UK
CA
USA
IND
_10_04_2024_16_38_50_427275.jpg)
Highlights
Collaboration with NHS Cancer Vaccine Launchpad to enhance patient recruitment for the SCOPE study
iSCIB B one plus DNA vaccine designed to work alongside checkpoint inhibitors in melanoma immunotherapy
Ongoing development of Modi‑one peptide vaccine and GlyMab antibody platform targeting solid tumours
The biotechnology sector drives medical innovation by developing novel therapies to address complex diseases. Immunotherapy, which harnesses the body’s own defences to target cancer cells, has emerged as a key frontier. Scancell Holdings PLC (LSE:SCLP) is advancing its cancer vaccine programmes through strategic alliances and a diversified pipeline.
NHS Partnership for Patient Recruitment
Scancell has forged a unique alliance with the NHS Cancer Vaccine Launchpad to streamline enrolment for its SCOPE study. This collaboration makes use of NHS networks and digital platforms to identify eligible advanced melanoma patients more efficiently than traditional routes. By integrating patient registries and clinical trial outreach, the partnership seeks to boost participation rates and reduce the timeframe required to reach study milestones.
iSCIB B one plus Vaccine and Study Design
The SCOPE study evaluates the iSCIB B one plus DNA vaccine in combination with existing checkpoint inhibitor therapies. Vaccine administration involves intradermal delivery followed by a brief burst of energy to enhance uptake by immune cells. Multiple patient groups receive varied dosing schedules to establish optimal immune activation profiles. Trial endpoints include measurement of tumour response and assessment of immune cell populations within biopsy samples. Data collection prioritises safety observations and immunological markers to inform subsequent clinical stages.
Modi‑one Peptide Vaccine and GlyMab Platform Progress
Alongside the DNA vaccine, Scancell is progressing Modi‑one, a peptide‑based immunotherapy designed to target modified tumour antigens found across multiple cancer types. Early‑stage results have shown durable immune responses in a range of solid tumour settings. The GlyMab antibody platform, including the SC one three four programme for small cell lung carcinoma, is also moving through preclinical and clinical evaluation. Engineering efforts focus on optimising binding affinity and half‑life extension to maximise tumour targeting.
Leadership and Strategic Priorities
Under CEO Phillip L’Huillier, Scancell emphasises adherence to development timelines and regulatory engagement. Collaborative forums with healthcare authorities and clinical experts guide protocol adjustments and safety monitoring. Commercial teams work closely with manufacturing partners to secure vector supply and scalable production. Scientific advisory boards provide oversight on biomarker selection and trial design, ensuring data robustness and alignment with regulatory expectations. Continuous dialogue with patient advocacy groups supports transparent communications and addresses community needs.
